Gore Earns NIH Award for Research on Endocrine-disrupting Chemicals

Molecules and other objects floating around a human brain.
July 12, 2023
Andrea C. Gore, Ph.D., professor of pharmacology and toxicology and Vacek Chair in Pharmacology, recently earned an R35 RIVER grant award from the National Institute of Environmental Health Sciences (NIEHS) for her lab’s research on endocrine-disrupting chemicals (EDCs) and their effect on the brain. The NIEHS, which is one of the centers in the National Institutes of Health (NIH), awarded a total of $6,823,672 for eight years.

Faculty Earn State Grants for Cancer Research

A person in a lab.
September 21, 2022
The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.

Pharmacists: The Most Accessible Healthcare Provider, Unless You Have a Substance Use Disorder

White pill bottle with white pills on a black background.
August 23, 2022
P4 students, Megan Yeung, Kami Johnston and Morgan Murchison co-author a peer-reviewed blog in Pulses encouraging educators to adapt to reflect the specific needs of people who use drugs and patients with substance use disorders. This blog also highlights UT Pharmacy as a U.S. leader in substance use disorder and harm reduction education for Pharm.D. students.

Celebrating the Latest Awards, Appointments and Achievements from the UT Pharmacy Community

Pharmacy building on UT campus
July 5, 2022
From student scholarships to national recognition awards to prestigious appointments, the UT Pharmacy community has a lot to celebrate and be proud of right now.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Nixon and Hill Earn Faculty Promotions

A woman smiling and a man wearing glasses.
March 24, 2021
Two of the College of Pharmacy’s distinguished faculty were recently promoted due to their outstanding accomplishments in research, outreach and education. Dr. Kimberly Nixon of the Division of Pharmacology and Toxicology will assume the rank of professor and Dr. Lucas G. Hill of the Division of Pharmacy Practice will become a clinical associate professor.

Live Subject Testing Shows Promising Delivery Method for COVID-19 Antiviral Treatment

A microscopic image.
September 23, 2020
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.

New Delivery Method Could Make Niclosamide an Effective Antiviral to Treat COVID-19

Two men in suits smiling.
April 6, 2020
A team of researchers in the college, led by Robert O. (Bill) Williams III and Hugh D. Smyth, is investigating varying methods of drug delivery to repurpose existing drugs in order to treat and prevent serious COVID-19 virus symptoms in patients.